ESI-GROUP
8.6.2021 14:02:09 CEST | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI), a global player in virtual prototyping for industries, participates in the successful development phase of the Nivus made by Volkswagen do Brazil: 100% digitally and virtually – a world premiere. The process began before the pandemic and was completed during the COVID-19 period, applying all the sanitary measures in place. Thanks to Virtual Prototyping/Digital Development (a change in product development), time was shortened in about 10 months and saved a few million euros in prototype production costs: Would it be a shift in the industry?
Making the right decision, quickly and 100% digitally
Usually, when a new vehicle is developed, time and physical prototypes are required both during the design and assembly preparation phases. In the case of the Nivus, launched in a live broadcast by Volkswagen do Brazil in June 2020 to around 60 countries, the whole conception of the vehicle was made 100% virtually.
The state-of-the-art solution provided by ESI Group, based on its software IC.IDO
was one of the tools used to design reviews and engineering decisions in different departments (product development, operations, quality, etc). This allowed Volkswagen to make informed decisions regarding the car’s conception. It provided the automotive company with the opportunity to save time (shortened the car’s development in about 10 months) and investment (for example, only in the Virtual Prototype Laboratory there was a 65% reduction of costs compared to previous projects).
Virtual reality also conserves tons of paper, in which specifications for each part of a car were previously detailed.
Long before Nivus physically existed, the vehicle was already available digitally in the engineering computers. Considering that building a physical prototype takes 19 weeks, in which only a single vehicle variant is possible. For this vehicle, nine virtual variants were produced, in much less time, which made it possible to anticipate more efficient assembly procedures, reducing the number of processes in the simulations and avoiding errors, since all parts were previously tested with digital tools.
"We designed 100% of the Nivus with digital processes using, among others, ESI’s technology without the need to assemble a single physical prototype. In addition, with the drastic reduction of the development time, this solution helps us to integrate all our different teams, from various department (design, engineering, marketing, production, etc) in the same decision-making process. It was a more efficient but also more collaborative process. " explains Francisvaldo Gomes Aires, Prototyping Development Manager at Volkswagen do Brazil.
Virtual reality: A huge benefit during COVID-19
ESI demonstrated that even when the design phase is impacted, in this case by COVID-19, it is possible to continue with the project, since it is no longer a question of relying solely on physical reality. This opens up the possibility of experiencing the future with digitalization and technology for the project benefit.
“It’s a shift in the industrial production. For the first time, all phases of a car release, before the effective production, has been fully made virtually making the production feasible during Covid-19 time. While allowing Volkswagen to take all its design and manufacturing decisions virtually, we helped them produce faster, cheaper and in a more sustainable way. This was possible due to a strong support of our local Brazilian team and a mutual collaboration between ESI Brazil and Volkswagen do Brazil. We all feel proud to be part of this world-premiere alongside with Volkswagen and its partners.” declares Andreas Renner, Volkswagen Global Account Manager – ESI Group.
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI
http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005672/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
